MF59 adjuvant: the best insurance against influenza strain diversity (Q30402018)

21 June 2017

1 reference

title

MF59 adjuvant: the best insurance against influenza strain diversity (English)

1 reference

21 June 2017

2

Rino Rappuoli

1 reference

21 June 2017

Derek T O'Hagan

1

1 reference

21 June 2017

Ennio De Gregorio

series ordinal

3

1 reference

21 June 2017

Theodore Tsai

series ordinal

4

1 reference

21 June 2017

Giuseppe Del Giudice

series ordinal

5

1 reference

21 June 2017

1 April 2011

1 reference

Expert Review of Vaccines

21 June 2017

1 reference

21 June 2017

10

1 reference

21 June 2017

4

1 reference

21 June 2017

447-462

1 reference

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

21 June 2017

1 reference

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

21 January 2018

1 reference

Antibody response to influenza vaccination in the elderly: a quantitative review

21 January 2018

1 reference

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

21 January 2018

1 reference

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

21 January 2018

1 reference

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

21 January 2018

1 reference

A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly

21 January 2018

1 reference

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

21 January 2018

1 reference

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

21 January 2018

1 reference

A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens

21 January 2018

1 reference

MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates

21 January 2018

1 reference

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

21 January 2018

1 reference

Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets

21 January 2018

1 reference

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

21 January 2018

1 reference

Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice

21 January 2018

1 reference

Dendritic cells internalize vaccine adjuvant after intramuscular injection

21 January 2018

1 reference

The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells

21 January 2018

1 reference

Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis

21 January 2018

1 reference

Molecular and cellular signatures of human vaccine adjuvants.

21 January 2018

1 reference

The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine

21 January 2018

1 reference

Influenza vaccine: the challenge of antigenic drift.

21 January 2018

1 reference

An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine

21 January 2018

1 reference

Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

21 January 2018

1 reference

Real-time monitoring of the influenza vaccine field effectiveness

21 January 2018

1 reference

Research and development of universal influenza vaccines

21 January 2018

1 reference

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

21 January 2018

1 reference

Antibody recognition of a highly conserved influenza virus epitope

21 January 2018

1 reference

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

21 January 2018

1 reference

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine

21 January 2018

1 reference

Universal epitopes of influenza virus hemagglutinins?

21 January 2018

1 reference

21 January 2018

Safety of MF59 adjuvant

1 reference

Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis.

21 January 2018

1 reference

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis

21 January 2018

1 reference

Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands

21 January 2018

1 reference

Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness.

21 January 2018

1 reference

Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene

21 January 2018

1 reference

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

21 January 2018

1 reference

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

21 January 2018

1 reference

Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.

21 January 2018

1 reference

Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy

21 January 2018

1 reference

A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis

21 January 2018

1 reference

Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases.

21 January 2018

1 reference

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.

21 January 2018

1 reference

Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection

21 January 2018

1 reference

Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.

21 January 2018

1 reference

Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly

21 January 2018

1 reference

Seasonal and pandemic influenza: a 2007 update on challenges and solutions

21 January 2018

1 reference

Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans

21 January 2018

1 reference

Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets

21 January 2018

1 reference

Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development

21 January 2018

1 reference

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.

21 January 2018

1 reference

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

21 January 2018

1 reference

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

21 January 2018

1 reference

Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

21 January 2018

1 reference

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

21 January 2018

1 reference

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

21 January 2018

1 reference

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

21 January 2018

1 reference

Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

21 January 2018

1 reference

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

21 January 2018

1 reference

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

21 January 2018

1 reference

Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.

21 January 2018

1 reference

Response to a monovalent 2009 influenza A (H1N1) vaccine.

21 January 2018

1 reference

Responses to 2009 H1N1 vaccine in children 3 to 17 years of age.

21 January 2018

1 reference

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

21 January 2018

1 reference

Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children

21 January 2018

1 reference

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

21 January 2018

1 reference

Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages

21 January 2018

1 reference

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

21 January 2018

1 reference

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

21 January 2018

1 reference

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

21 January 2018

1 reference

Disquisitions of Original Antigenic Sin. I. Evidence in man

21 January 2018

1 reference

Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans

21 January 2018

1 reference

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

21 January 2018

1 reference

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

21 January 2018

1 reference

Vaccinate before the next pandemic?

21 January 2018

1 reference

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus

21 January 2018

1 reference

Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets

21 January 2018

1 reference

Seasonal influenza vaccine provides priming for A/H1N1 immunization

21 January 2018

1 reference

Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model

21 January 2018

1 reference

Prior infection with classical swine H1N1 influenza viruses is associated with protective immunity to the 2009 pandemic H1N1 virus

21 January 2018

1 reference

Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus.

21 January 2018

1 reference

Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus

21 January 2018

1 reference

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes

21 January 2018

1 reference

Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses

21 January 2018

1 reference

Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.11.23

1 reference

21 June 2017

1 reference